Inhaled corticosteroids may carry less risk of BMD reduction in postmenopausal women
Corticosteroid therapy is an effective treatment for asthma sufferers, but the use of systemic corticosteroids is known to increase the risk of osteoporotic fractures. A recent study published in the Journal of Allergy and Clinical Immunology suggests that moderate doses of inhaled corticosteroids (ICs) carry less risk than traditional oral corticosteroid (OC) therapy with respect to reduction of bone mineral density (BMD) in postmenopausal women. This assertion is based on the premise that the lowest daily dose of IC sufficient to control the patient's asthma is used.
Phase 3 data fueled buzz about Moderna’s personalized melanoma “vaccine.” paired with Merck's Keytruda. The drama surrounding intismeran included an embargo violation and headlines that the treatment hadn't lived up to its hype.
Will Carroll, Pharm.D., of Sutter Health says pharmacy is often handed strategy to execute instead of shaping it, and must show value in C-suite terms.
Ty Gluckman, M.D., says undertesting and undertreatment are the biggest gaps in lipid care and calls on leaders to invest in cardiovascular prevention.
Ty Gluckman, M.D., says the 2026 dyslipidemia guideline brings back risk-based LDL goals, and clinical inertia, not access, is now the biggest barrier.